Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir Intensification in Acute and Early HIV-1 Infection
NCT00781287Phase 4Terminated
- Sponsor
- University of Washington
- Start
- Feb 2009
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by University of Washington. Primary endpoint: Number of HIV-1 infected CD4+ T-cells measured by a quantitative HIV-1 DNA PCR assay at 96 weeks. Started Feb 2009; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00781287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781287.